Inhibition of Osteoarthritis by Adipose‐Derived Stromal Cells Overexpressing Fra‐1 in Mice
Open Access
- 11 September 2015
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 68 (1) , 138-151
Abstract
Objective: To determine whether overexpression of the activator protein 1 (AP‐1) transcription factor Fra‐1 in adipose‐derived stromal cells (ADSCs) is an effective treatment of collagenase‐induced osteoarthritis (OA).Methods: OA was induced by injection of collagenase into the knee joints of male C57BL/6 mice. ADSCs were isolated from the inguinal fat pads of 8‐week‐old wild‐type or Fra‐1–transgenic mice and injected into the knee joints of mice with collagenase‐induced OA 7 days after OA induction. Histologic analyses of cartilage destruction and chondrocyte cell death were performed. Adipogenic differentiation capacity was evaluated, gene expression was analyzed, and cytokine profiling was performed in stromal vascular fractions (SVFs) and ADSCs.Results: OA‐related cartilage destruction and chondrocyte cell death were significantly reduced in mouse knee joints treated with ADSCs from Fra‐1–transgenic mice compared to mouse knee joints treated with ADSCs from wild‐type mice. This effect did not result from the higher number of adipogenic progenitors observed in SVFs from Fra‐1–transgenic compared to wild‐type mouse fat pads, since injection of wild‐type mouse ADSCs enriched for adipogenic progenitors did not show any additional chondroprotective effects compared to nonsorted ADSCs. However, Fra‐1–transgenic mouse ADSCs showed decreased adipogenic differentiation capacity. Moreover, Fra‐1 significantly inhibited proinflammatory interleukin‐6 and pentraxin 3 expression, while increasing the expression of extracellular matrix proteins, such as periostin and spondin 1. These findings suggest that Fra‐1 overexpression leads to an increased chondroprotective effect of ADSCs in OA.Conclusion: ADSCs overexpressing Fra‐1 effectively protect against OA. Our data indicate that genetic modifications of ADSCs, such as Fra‐1 overexpression, may improve their potential to protect articular cartilage against OA‐mediated damage.Keywords
Funding Information
- DFG (Emmy Noether Programme grant)
- European Union (Seventh Framework Programme projects Adipoa, Masterswitch, and Marie Curie ITN Osteoimmune, and the Innovative Medicines Initiative project BTCure)
This publication has 35 references indexed in Scilit:
- Intra-articular delivery of adipose derived stromal cells attenuates osteoarthritis progression in an experimental rabbit modelArthritis Research & Therapy, 2013
- Antiinflammatory and chondroprotective effects of intraarticular injection of adipose‐derived stem cells in experimental osteoarthritisArthritis & Rheumatism, 2012
- Osteoarthritis: A disease of the joint as an organArthritis & Rheumatism, 2012
- Pharmacologic therapy for osteoarthritis—the era of disease modificationNature Reviews Rheumatology, 2010
- Cartilage homeostasis in health and rheumatic diseasesArthritis Research & Therapy, 2009
- Adipose‐derived stem cell: a better stem cell than BMSCCell Biochemistry and Function, 2008
- Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part IIArthritis & Rheumatism, 2007
- OsteoarthritisJournal of Cellular Physiology, 2007
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006
- Articular cartilage repair: basic science and clinical progress. A review of the current status and prospectsOsteoarthritis and Cartilage, 2002